Focus: Hologic is a $4.0B medical device company headquartered in Massachusetts, specializing in diagnostics and surgical systems across women's health, oncology, and infectious disease. The company operates at significant scale with 5,001-10,000 employees and maintains a strong balance sheet as a public entity.
Profile data last refreshed 35m ago · AI intelligence enriched 2mo ago
No open roles listed right now. Follow Hologic to get notified when they start hiring — the background below is worth knowing for when they do.
Recently secured FDA approval for primary HPV screening, representing a major commercial inflection point for cervical cancer prevention.
Help build intelligence for Hologic
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Hologic's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Core franchise technology with multiple clinical studies validating efficacy; reduces recall rates and improves cancer detection.
Established women's health procedure with strong installed base; represents recurring revenue opportunity through physician adoption.
Apitegromab for lean mass preservation during tirzepatide-induced weight loss: a randomized, double-blind, placebo-controlled phase 2 trial - Nature
Apitegromab for lean mass preservation during tirzepatide-induced weight loss: a randomized, double-blind, placebo-controlled phase 2 trial Nature
FDA Approves First Oral COVID-19 PEP Drug, Xocova - Infectious Disease Special Edition
FDA Approves First Oral COVID-19 PEP Drug, Xocova Infectious Disease Special Edition
Hologic to Present New Data at ASCO 2026 Demonstrating the Clinical Impact of the Breast Cancer Index® Test on Extended Endocrine Therapy Decisions - Cadillac News
Hologic to Present New Data at ASCO 2026 Demonstrating the Clinical Impact of the Breast Cancer Index® Test on Extended Endocrine Therapy Decisions Cadillac News
8-K Filing: Carlyle Credit Income Fund (CCID, CCIF) (CIK 0001517767) — EX-99.2
EX-99.2
Hologic's international momentum takes shape: will execution pay off? - MSN
Hologic's international momentum takes shape: will execution pay off? MSN
New Hampshire Justices Dissect Hologic’s Business Tax Method - Bloomberg Law News
New Hampshire Justices Dissect Hologic’s Business Tax Method Bloomberg Law News
Showing 6 of 10 news items
No open positions listed yet. Check their careers page directly.
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Development and genomic characterization of a diverse HIV-1 variant reference panel for nucleic acid-based testing.
Mycoplasma genitalium infection and adverse perinatal outcomes.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo